

INVERNESS MEDICAL INNOVATIONS INC

Form 8-K

March 04, 2010

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 4, 2010**

**Inverness Medical Innovations, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

**001-16789**

**04-3565120**

(State or other jurisdiction  
of incorporation)

(Commission file number)

(IRS Employer  
Identification No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 647-3900**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-99.1 Unaudited pro forma condensed combined statement of operations

---

**Table of Contents**

**Item 9.01 Financial Statements and Exhibits.**

*(b) Pro Forma Financial Information*

In connection with the Registration Statement on Form S-4 (File No. 333-164897) (as amended from time to time, the Registration Statement ) of Inverness Medical Innovations, Inc. (the Company ), the Company is providing an unaudited pro forma condensed combined statement of operations of the Company for the year ended December 31, 2009, giving pro forma effect to the Company's acquisition of the second territory business of ACON Laboratories, Inc., AZURE Institute, Inc., Oakville Hong Kong Co., Ltd., and ACON Biotech (Hangzhou) Co., Ltd. (the ACON Second Territory Business ) on April 30, 2009, which is attached hereto as Exhibit 99.1 and incorporated by reference herein and in the Registration Statement.

*(d) Exhibits*

**Exhibit No. Description**

99.1*	Unaudited pro forma condensed combined statement of operations of the Company for the year ended December 31, 2009 giving pro forma effect to the acquisition of the ACON Second Territory Business on April 30, 2009
-------	---

\* furnished  
herewith

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL  
INNOVATIONS, INC.

BY: /s/ Jay McNamara  
Jay McNamara  
Senior Counsel Corporate & Finance

Dated: March 4, 2010

---

**Table of Contents**

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1\* Unaudited pro forma condensed combined statement of operations of the Company for the year ended December 31, 2009 giving pro forma effect to the acquisition of the ACON Second Territory Business on April 30, 2009

\* furnished  
herewith